1. GPCR/G Protein
  2. Prostaglandin Receptor
  3. Beraprost sodium

Beraprost sodium 

Cat. No.: HY-13569A Purity: 99.88%
Handling Instructions

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation.

For research use only. We do not sell to patients.

Beraprost sodium Chemical Structure

Beraprost sodium Chemical Structure

CAS No. : 496807-11-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 365 In-stock
Estimated Time of Arrival: December 31
1 mg USD 95 In-stock
Estimated Time of Arrival: December 31
5 mg USD 395 In-stock
Estimated Time of Arrival: December 31
10 mg USD 750 In-stock
Estimated Time of Arrival: December 31
25 mg USD 1500 In-stock
Estimated Time of Arrival: December 31
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Beraprost sodium, a prostacyclin analog, is a stable and orally active prodrug of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation[1].

IC50 & Target

prodrug of PGI2; Vasodilator[1]

In Vitro

Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity[1]. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions[1].

In Vivo

Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis[1].

Animal Model: 6-8-week-old C57Bl/6J Male Mice[1]
Dosage: 0.6 mg/kg
Administration: Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days
Result: Mitigated the development of renal interstitial fibrosis.
Clinical Trial
Molecular Weight

420.47

Formula

C₂₄H₂₉NaO₅

CAS No.

496807-11-5

SMILES

CC#CCC(C)[[email protected]](O)/C=C/[[email protected]@H]1[[email protected]@]2([H])C3=CC=CC(CCCC(O[Na])=O)=C3O[[email protected]@]2([H])C[[email protected]]1O.[Relative stereochemistry]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (594.57 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3783 mL 11.8915 mL 23.7829 mL
5 mM 0.4757 mL 2.3783 mL 4.7566 mL
10 mM 0.2378 mL 1.1891 mL 2.3783 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution

  • 3.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution

*All of the co-solvents are provided by MCE.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

BeraprostProstaglandin ReceptorpulmonaryarterialhypertensionChronickidneydiseaseCKDInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product name:
Beraprost sodium
Cat. No.:
HY-13569A
Quantity:
MCE Japan Authorized Agent: